Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies
Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies
Active, not recruiting · NCT04395079 · Registry updated 2026-07-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies | Metastatic Malignant Female Reproductive System Neoplasm; Platinum-Resistant Malignant Female Reproductive System Neoplasm; Recurrent Malignant Female Reproductive System Neoplasm; Refractory Malignant Female Reproductive System Neoplasm | Active, not recruiting | Phase 2 | 2026-07-17 | NCT04395079 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AstraZeneca | 806 |
| Jonsson Comprehensive Cancer Center | 115 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| UCLA / Jonsson Comprehensive Cancer Center | Los Angeles | United States | 126 |